The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,050.00
Bid: 12,038.00
Ask: 12,040.00
Change: -106.00 (-0.87%)
Spread: 2.00 (0.017%)
Open: 12,092.00
High: 12,178.00
Low: 12,010.00
Prev. Close: 12,156.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TOP NEWS: WHO Backs AstraZeneca Jab As Expert Trades Barbs With US

Wed, 10th Feb 2021 15:59

(Alliance News) - The World Health Organization on Wednesday offered its backing to the coronavirus vaccine made by embattled drug company AstraZeneca PLC, as one of its experts exchanged barbs with the US government over a controversial mission to probe the pandemic's origins in China.

The WHO said AstraZeneca's jabs could be used on people aged over 65 and also in places where new variants of Covid-19 are circulating, following recent questions over the efficacy of the British-Swedish firm's vaccine.

And there was further good news for AstraZeneca as the company announced it would work with German firm IDT Biologika to produce more vaccines for Europe, where shortages of doses have sparked a bitter dispute with the EU. 

Covid-19 has killed more than 2.3 million people since emerging in China in late 2019, exerting a firm grip over people's lives across the world with lockdowns, curfews and business closures.

Germany looked set to prolong its restrictions as the EU passed 500,000 deaths on Wednesday, with many EU countries struggling to get momentum behind their vaccine rollouts. 

The EU's top official admitted in a public forum for the first time that the bloc had botched some aspects of its vaccine strategy. 

"We were late to authorise. We were too optimistic when it came to massive production," European Commission chief Ursula von der Leyen told the European Parliament. 

Even Russia, widely hailed for its homegrown Sputnik V jab, had only managed to fully vaccinate just over two million, two months into its programme. 

Questions over the handling of the initial outbreak have meanwhile sparked an intense diplomatic row between Washington and Beijing. 

A joint Chinese-WHO mission to the ground zero city of Wuhan wrapped up on Tuesday without any concrete answers, and US officials said they would not accept the findings before verification with their own intelligence. 

The jibe prompted WHO team member Peter Daszak to tweet: "Please don't rely too much on US intel: increasingly disengaged under Trump & frankly wrong on many aspects." 

Hundreds of millions of people are still living under severe restrictions including curfews and full lockdowns, and many businesses are beginning to take a more strident tone with their governments. 

"We are suffocating," read a banner at a rally in Greece's capital Athens, where hundreds of restaurant owners dropped their keys in a box to give to the government as a symbol of their despondency. 

Greece, which has been under severe restrictions since late last year, will face an even tighter regime from Thursday as Prime Minister Kyriakos Mitsotakis warned of a third wave. 

Frustrations were also boiling over in Israel, where security forces and ultra-orthodox Jews clashed in the latest in a series of protests against coronavirus restrictions.

"Stop the harassment of religion on health grounds," read one banner, highlighting that curbs are being lifted more slowly in ultra-orthodox districts because of higher infection rates. 

Israel has so far given more than 40% of its population at least one vaccine shot, leaving other parts of the world to play catch-up. 

Peru on Tuesday began administering shots developed by China's Sinopharm, while Argentina approved the Indian-made version of the AstraZeneca vaccine. 

South Korea on Wednesday also authorised the AstraZeneca shot for people aged 18 and above, including over-65s. 

Japan will start vaccinations next week – most likely the Pfizer/BioNTech jab – but it is scrambling to secure suitable syringes so doses are not wasted.

AstraZeneca has faced a tough few weeks, with European leaders casting doubt on the efficacy of its jabs for over-65s and a small South African study suggesting it performed badly against their local strain. 

Before Wednesday's announcements from the WHO, South African officials said they were considering selling or swapping the jabs they had already bought, opting to stock up on another vaccine made by rival Johnson & Johnson.

"There are already countries who are asking to sell it to them," said Health Minister Zweli Mkhize.

As vaccine rollouts rumble on, governments still face the thorny issue of persuading restless populations to abide by social-distancing rules – a particular problem this weekend when couples will look for a way to mark Valentine's Day on Sunday.

Thailand's capital Bangkok has banned people from getting married on the day, usually a popular time for weddings.

In Brussels, entrepreneurs are trying to enable some kind of celebration, with hotels converting rooms into private dining salons for two. 

"We're over the moon about being here tonight, just like in a restaurant," said Marine Deroo, a 34-year-old who tried out the concept ahead of Valentine's Day. 

source: AFP

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Read more
3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts.

Read more
3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.

Read more
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

Read more
29 Apr 2024 10:02

LONDON BROKER RATINGS: Deutsche Bank likes Frasers; Barclays cuts JD

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
29 Apr 2024 09:13

AstraZeneca makes progress with Truqap and Enhertu cancer treatments

(Alliance News) - AstraZeneca PLC on Monday said its Truqap drug has been recommended for approval in the EU to treat a form of breast cancer, while also noting trial results for its Enhertu offering.

Read more
29 Apr 2024 07:50

LONDON BRIEFING: Hipgnosis Songs Fund backs new Blackstone bid

(Alliance News) - London's FTSE 100 is called to open higher on Monday, with heady gains for US tech stocks on Friday brightening the mood in Europe and Asia at the start of the new week.

Read more
29 Apr 2024 07:24

AstraZeneca makes progress with two breast cancer treatments

(Sharecast News) - AstraZeneca issued favourable updates on two of its breast cancer treatments on Monday - 'Truqap', or capivasertib, and 'Enhertu', or trastuzumab deruxtecan - following encouraging results from respective phase three trials.

Read more
26 Apr 2024 09:33

LONDON BROKER RATINGS: Peel Hunt cuts ConvaTec to 'reduce'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

Read more
25 Apr 2024 16:57

LONDON MARKET CLOSE: FTSE 100 shakes off red-hot US inflation gauge

(Alliance News) - London's FTSE 100 outperformed on Thursday, enjoying a solid rise on largely well-received corporate earnings and a share price jump for miner Anglo American after it received a takeover bid from peer BHP.

Read more
25 Apr 2024 15:14

London close: Stocks finish mixed as US GDP growth slows

(Sharecast News) - London's stock markets finished with a mixed performance on Thursday, as investors digested a slower-than-expected GDP growth reading from the United States, while a slew of well-received earnings underpinned the top-flight index.

Read more
25 Apr 2024 11:50

LONDON MARKET MIDDAY: FTSE 100 hits high on offer for Anglo American

(Alliance News) - The FTSE 100 was outperforming European markets at midday on Thursday, with the index boosted to a record high thanks to takeover talks.

Read more
25 Apr 2024 10:33

AstraZeneca leaps after smashing first-quarter forecasts

Q1 revenue up 19% to $12.68 bln

*

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.